AOLS (Aeolus Pharmaceuticals) Liabilities-to-Assets : 0.74 (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aeolus Pharmaceuticals Liabilities-to-Assets?

Aeolus Pharmaceuticals AOLS -99.00% Liabilities-to-Assets is 0.74 as of Jun. 2017.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Aeolus Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2017 was $0.59 Mil. Aeolus Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2017 was $0.79 Mil. Therefore, Aeolus Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2017 was 0.74.

Aeolus Pharmaceuticals  (OTCPK:AOLS) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Aeolus Pharmaceuticals Liabilities-to-Assets Related Terms

Aeolus Pharmaceuticals Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Liabilities-to-Assets Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.19 0.64 0.56 1.48 0.23

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.23 0.19 0.36 0.74

AOLS vs RDGL, PCYN, YBAO: Liabilities-to-Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aeolus Pharmaceuticals Liabilities-to-Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's Liabilities-to-Assets falls into.


Aeolus Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Aeolus Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Sep. 2016 is calculated as:

Liabilities-to-Assets (A: Sep. 2016 )=Total Liabilities/Total Assets
=0.972/4.167
=0.23

Aeolus Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2017 is calculated as

Liabilities-to-Assets (Q: Jun. 2017 )=Total Liabilities/Total Assets
=0.587/0.794
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.74 mean?
Aeolus Pharmaceuticals (AOLS) has a Liabilities-to-Assets of 0.74 as of Jun. 2017. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Liabilities-to-Assets too high?
Aeolus Pharmaceuticals' current Liabilities-to-Assets is 0.74.
How does Aeolus Pharmaceuticals' Liabilities-to-Assets compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Liabilities-to-Assets of 0.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Liabilities-to-Assets is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Liabilities-to-Assets of 0.74. The current Liabilities-to-Assets is 0.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Liabilities-to-Assets is 0.74 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.